Kiasita 50 Tablet contains Sitagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's ability to regulate blood glucose levels by increasing the levels of incretin hormones. These hormones stimulate insulin release from pancreatic beta cells and decrease glucagon secretion from alpha cells in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Kiasita 50 is indicated as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin when diet and exercise alone do not provide adequate glycemic control. It is particularly beneficial for patients who require improved postprandial and fasting blood glucose regulation. The recommended dosage should be individualized based on patient response and renal function, with dose adjustments necessary in cases of renal impairment. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections, while serious side effects are rare but may include pancreatitis. Kiasita 50 should be used under medical supervision with regular monitoring of blood glucose levels and renal function to ensure safety and efficacy.